Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Decompensated Liver Cirrhosis Clear all
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis

NCT06764966
View directory record Official record
Conditions
Decompensated Liver Cirrhosis, Cirrhosis, Decompensated Cirrhosis of Liver, Decompensated Cirrhosis and Ascites
Interventions
Atorvastatin 20 mg, Placebo
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

NCT01904409
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)

NCT03540771
View directory record Official record
Conditions
End Stage Liver Disease, Decompensated Cirrhosis of Liver
Interventions
Palliative Care
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 120 Years
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 30, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

Hospital @ Home Model of Care for Cirrhosis

NCT06396897
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Indiana University Health Hospital at Home Program
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Completed No phase listed Observational

Bleeding in Hospitalized Patients With Liver Disease Undergoing Invasive Procedures

NCT04076605
View directory record Official record
Conditions
Bleeding, Procedural Complication, Cirrhosis, Liver, Coagulation Disorder, Blood
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Sep 30, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

NCT06937307
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Interventions
Droxidopa capsules, Placebo
Drug · Other
Lead sponsor
Giuseppe Cullaro, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.

NCT00275652
View directory record Official record
Conditions
Hepatitis B, Cirrhosis
Interventions
LdT (Telbivudine) and lamivudine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients

NCT05928624
View directory record Official record
Conditions
Cirrhosis, Liver, Portal Hypertension, Ascites Hepatic
Interventions
Withings Home Blood Pressure Device and Scale, Standard of Care
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 30, 2026, 5:06 AM EDT
Completed No phase listed Observational

Shear Wave Elastography

NCT04493346
View directory record Official record
Conditions
Heart Failure, Transplant; Failure, Heart, Decompensated Heart Failure, Fibrosis, Liver, Cirrhosis, Liver
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 30, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

NCT04112199
View directory record Official record
Conditions
Ascites, Decompensated Cirrhosis
Interventions
BIV201 continuous infusion
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 30, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

NCT06082843
View directory record Official record
Conditions
Hypertension, Portal, Liver Cirrhosis
Interventions
Placebo, Avenciguat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Pasadena, California • Rialto, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 30, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

NCT06812390
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Albumin infusion (25% albumin), Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Anahita Rabiee MD MHS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

NCT03451292
View directory record Official record
Conditions
Decompensated Cirrhosis and Ascites
Interventions
Albutein 20%, SMT
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Coronado, California • Miami, Florida • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Not applicable Interventional

CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis

NCT04205396
View directory record Official record
Conditions
Caregivers
Interventions
Written emotional disclosure, Resilience training, No treatment
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Sep 30, 2026, 5:06 AM EDT
Not yet recruiting Not applicable Interventional

Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis

NCT07755059
View directory record Official record
Conditions
Ascites, Liver Cirrhosis, Hypertension, Portal
Interventions
Proximal Splenic Artery Embolization
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites

NCT02608658
View directory record Official record
Conditions
Cirrhosis of the Liver, Ascites, Spontaneous Bacterial Peritonitis
Interventions
Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Sep 30, 2026, 5:06 AM EDT
Recruiting No phase listed Observational

VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)

NCT07390344
View directory record Official record
Conditions
Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
Interventions
GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

NCT05484206
View directory record Official record
Conditions
Hepatic Impairment, Cirrhosis
Interventions
VIR-2218, VIR-3434
Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rialto, California • Tustin, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 30, 2026, 5:06 AM EDT
Not listed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

NCT03205345
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Emricasan (25 mg), Emricasan (5 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
76
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 30, 2026, 5:06 AM EDT
Terminated No phase listed Observational

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

NCT03479125
View directory record Official record
Conditions
Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Sep 30, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

NCT00076336
View directory record Official record
Conditions
Hepatitis, Hepatitis B, Chronic, Cirrhosis
Interventions
Telbivudine, Lamivudine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Sep 30, 2026, 5:06 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma

NCT03908255
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Liver Failure
Interventions
Branch Chain Amino Acid, maltodextrin
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Sep 30, 2026, 5:06 AM EDT